4QVX

Discovery of a Potent and Selective BCL-XL Inhibitor That Demonstrates Thrombocytopenia and Inhibits Tumor Growth in Vivo

Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.1 Å
  • R-Value Free: 0.257 
  • R-Value Work: 0.191 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history. 

Literature

Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity.

Tao, Z.F., Hasvold, L., Wang, L., Wang, X., Petros, A.M., Park, C.H., Boghaert, E.R., Catron, N.D., Chen, J., Colman, P.M., Czabotar, P.E., Deshayes, K., Fairbrother, W.J., Flygare, J.A., Hymowitz, S.G., Jin, S., Judge, R.A., Koehler, M.F., Kovar, P.J., Lessene, G., Mitten, M.J., Ndubaku, C.O., Nimmer, P., Purkey, H.E., Oleksijew, A., Phillips, D.C., Sleebs, B.E., Smith, B.J., Smith, M.L., Tahir, S.K., Watson, K.G., Xiao, Y., Xue, J., Zhang, H., Zobel, K., Rosenberg, S.H., Tse, C., Leverson, J.D., Elmore, S.W., Souers, A.J.

(2014) ACS MED.CHEM.LETT. 5: 1088-1093

  • DOI: 10.1021/ml5001867

  • PubMed Abstract: 

    • A-1155463, a highly potent and selective BCL-XL inhibitor, was discovered through nuclear magnetic resonance (NMR) fragment screening and structure-based design. This compound is substantially more potent against BCL-XL-dependent cell lines relative ...

    A-1155463, a highly potent and selective BCL-XL inhibitor, was discovered through nuclear magnetic resonance (NMR) fragment screening and structure-based design. This compound is substantially more potent against BCL-XL-dependent cell lines relative to our recently reported inhibitor, WEHI-539, while possessing none of its inherent pharmaceutical liabilities. A-1155463 caused a mechanism-based and reversible thrombocytopenia in mice and inhibited H146 small cell lung cancer xenograft tumor growth in vivo following multiple doses. A-1155463 thus represents an excellent tool molecule for studying BCL-XL biology as well as a productive lead structure for further optimization.

    Organizational Affiliation: 

    AbbVie, Inc. , 1 North Waukegan Road, North Chicago, Illinois 60064 United States.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Bcl-2-like protein 1
A, B
167Homo sapiensMutation(s): 0 
Gene Names: BCL2L1 (BCL2L, BCLX)
Find proteins for Q07817 (Homo sapiens)
Go to Gene View: BCL2L1
Go to UniProtKB:  Q07817
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
3CQ
Query on 3CQ
Download SDF File 
Download CCD File 
A, B
2-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydroisoquinolin-2(1H)-yl]-5-(3-{4-[3-(dimethylamino)prop-1-yn-1-yl]-2-fluorophenoxy}propyl)-1,3-thiazole-4-carboxylic acid
C35 H32 F N5 O4 S2
SOYCFODXNRVBTI-UHFFFAOYSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
3CQKi: <0.01 nM BINDINGMOAD
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.1 Å
  • R-Value Free: 0.257 
  • R-Value Work: 0.191 
  • Space Group: C 2 2 21
Unit Cell:
Length (Å)Angle (°)
a = 73.107α = 90.00
b = 90.955β = 90.00
c = 83.736γ = 90.00
Software Package:
Software NamePurpose
BUSTER-TNTrefinement
PROCESSdata reduction
ADSCdata collection
PROCESSdata scaling
MOLREPphasing

Structure Validation

View Full Validation Report or Ramachandran Plots


View more in-depth experimental data

Entry History 

Deposition Data

  • Deposited Date: 2014-07-16 
  • Released Date: 2015-07-22 
  • Deposition Author(s): Park, C.H.

Revision History 

  • Version 1.0: 2015-07-22
    Type: Initial release
  • Version 1.1: 2017-07-26
    Type: Refinement description, Source and taxonomy